Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective-Reference-Cited by-同舟云学术

Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective

Published:2017-10-23 Issue:1 Volume:11 Page:21-27
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Austin Christopher P.¹,Cutillo Christine M.¹,Lau Lilian P.L.²,Jonker Anneliene H.²,Rath Ana²³,Julkowska Daria⁴,Thomson David⁵,Terry Sharon F.⁶,de Montleau Béatrice⁷,Ardigò Diego⁸,Hivert Virginie⁷,Boycott Kym M.⁹,Baynam Gareth¹⁰¹¹,Kaufmann Petra¹,Taruscio Domenica¹²,Lochmüller Hanns¹³,Suematsu Makoto¹⁴,Incerti Carlo¹⁵,Draghia-Akli Ruxandra¹⁶¹⁷,Norstedt Irene¹⁶,Wang Lu¹⁸,Dawkins Hugh J.S.¹⁹,

Affiliation:

1. National Center for Advancing Translational Sciences (NCATS); National Institutes of Health (NIH); Bethesda Maryland USA

2. IRDiRC Scientific Secretariat; Inserm-US14; Rare Diseases Platform; Paris France

3. Orphanet; Inserm-US14; Rare Diseases Platform; Paris France

4. Agence Nationale de la Recherche (ANR); Paris France

5. Shire; Lexington Massachusetts USA (until April 2017)

6. Genetic Alliance; Washington DC USA

7. EURORDIS-Rare Diseases Europe; Paris France

8. Corporate Drug Development; Chiesi Farmaceutici S.p.A.; Italy

9. Children's Hospital of Eastern Ontario Research Institute; University of Ottawa; Ottawa Canada

10. Genetic Services of Western Australia; King Edward Memorial Hospital; Perth Australia

11. Western Australian Register of Developmental Anomalies; Perth Australia

12. National Centre for Rare Diseases; Istituto Superiore di Sanità; Rome Italy

13. Institute of Genetic Medicine; Newcastle University; Newcastle upon Tyne UK

14. Japan Agency for Medical Research and Development (AMED); Tokyo Japan

15. Sanofi Genzyme; Cambridge Massachusetts USA

16. Directorate General for Research and Innovation (DG RTD); European Commission; Brussels Belgium (until April 2017)

17. Merck & Co. Inc.; Upper Gwynedd; Pennsylvania USA (from June 2017)

18. National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH); Bethesda Maryland USA

19. Office of Population Health Genomics; Public Health Division; Department of Health; Government of Western Australia; Perth Australia

Funder

European Commission FP7 contract, “SUPPORT-IRDiRC”

European Commission FP7 contract, “RD-Connect”

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12500/fullpdf

Reference30 articles.

1. Rare-disease project has global ambitions;Abbott;Nature,2011

2. Progress in rare diseases research 2010-2016: an IRDiRC perspective;Dawkins;Clin. Trans. Sci.,2018

3. 3rd IRDiRC Conference 2017 http://www.irdirc-conference.org

4. The importance of international collaboration for rare diseases research-a European perspective;Julkowska;Gene Ther.,2017

5. International cooperation to enable the diagnosis of all rare genetic diseases;Boycott;Am. J. Hum. Genet,2017

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Coding undiagnosed rare disease patients in health information systems: recommendations from the RD-CODE project;Orphanet Journal of Rare Diseases;2024-01-27

2. Artificial intelligence and database for NGS-based diagnosis in rare disease;Frontiers in Genetics;2024-01-25

3. Time to diagnosis and determinants of diagnosis delays of people living with a rare disease: a Rare Barometer retrospective patient survey;2024-01-15

4. Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care;BioTech;2024-01-03

5. Emotional journey of patients with specified intractable diseases in Japan;Intractable & Rare Diseases Research;2024